Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : analysts and calls -- ML -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (168)	10/3/2005 8:59:52 PM
From: tom pope	Respond to of 238

And KERX. Something goosed KERX today. Maybe this? Keryx Biopharmaceuticals (KERX, $15.76, C-1-9) Initiate with a Buy and a $24 PT. Believe the Stock is Undervalued. KRX- 101 (oral drug) is in a pivotal phase III & IV clinical registration program for the treatment of nephropathy, a deterioration of kidney structure in 30% of diabetics. Estimate that if the clinical trials are successful, KRX-101 could be approved in late 2007 or early 2008 and potentially reach peak sales of $1 billion or more. KERX valuation depends heavily on KRX-101's approval and successful commercialization. We recommend the stock for investors with a high risk tolerance.